CXCL10 and amyotrophic lateral sclerosis: For example, Tregs expressing integrin protein CD11a, in the case of CK0803 for trial NCT05695521, have been used to target the CXCR3/CXCL10 axis with the aim of engaging the inflamed microglia in patients with amyotrophic lateral sclerosis (ALS).